Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas

NCT00589381 Phase 1 COMPLETED

RATIONALE: Drugs used in chemotherapy, such as fenretinide Lym-X-Sorb™ , work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide Lym-X-Sorb™ in treating patients with recurrent or resistant solid tumors or lymphoma.

Details

Lead sponsor	National Institutes of Health Clinical Center (CC)
Phase	Phase 1
Status	COMPLETED
Enrolment	30
Start date	2007-08
Completion	2011-03

Conditions

• Lymphoma
• Unspecified Adult Solid Tumor, Protocol Specific

Interventions

• fenretinide lipid matrix

Primary outcomes

• Maximum tolerated dose of 4-HPR/LXS oral powder
• Safety
• Toxicity

Countries

United States